HC Wainwright Analysts Give NovaBay Pharmaceuticals, Inc. (NBY) a $6.00 Price Target

HC Wainwright set a $6.00 target price on NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) in a report published on Wednesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts also recently issued reports about the company. Zacks Investment Research upgraded NovaBay Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, August 16th. Maxim Group reiterated a hold rating on shares of NovaBay Pharmaceuticals in a research note on Friday, August 11th. ValuEngine lowered shares of NovaBay Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, September 1st. Finally, Roth Capital set a $5.00 price target on shares of NovaBay Pharmaceuticals and gave the stock a buy rating in a research note on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $6.33.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) opened at $4.60 on Wednesday. NovaBay Pharmaceuticals has a 52-week low of $2.25 and a 52-week high of $5.00.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.09). NovaBay Pharmaceuticals had a negative net margin of 42.16% and a negative return on equity of 184.30%. The firm had revenue of $4.09 million during the quarter, compared to analyst estimates of $4.69 million.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Analysts Give NovaBay Pharmaceuticals, Inc. (NBY) a $6.00 Price Target” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/19/hc-wainwright-analysts-give-novabay-pharmaceuticals-inc-nby-a-6-00-price-target.html.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Analyst Recommendations for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply